HC Wainwright Has Negative Opinion of DMAC FY2026 Earnings

DiaMedica Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright lowered its FY2026 earnings forecast for DiaMedica Therapeutics to a loss of $0.81 per share, from a prior estimate of $0.80, while maintaining a Buy rating and $12 price target.
  • DiaMedica reported a quarterly loss of $0.21 per share, matching consensus. Analyst views are mixed: two rate the stock Buy and one Sell, resulting in a consensus Hold rating and a $12 average target.
  • DMAC shares opened at $8.38 and were up 0.6%; institutional investors and hedge funds own about 10.12% of the company.
  • MarketBeat previews top five stocks to own in December.

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Free Report) - Equities research analysts at HC Wainwright dropped their FY2026 earnings estimates for shares of DiaMedica Therapeutics in a report issued on Monday, November 16th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings of ($0.81) per share for the year, down from their previous estimate of ($0.80). HC Wainwright currently has a "Buy" rating and a $12.00 target price on the stock. The consensus estimate for DiaMedica Therapeutics' current full-year earnings is ($0.84) per share. HC Wainwright also issued estimates for DiaMedica Therapeutics' Q4 2026 earnings at ($0.23) EPS, FY2027 earnings at ($0.77) EPS, FY2028 earnings at ($0.65) EPS and FY2029 earnings at ($0.28) EPS.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.21) earnings per share for the quarter, hitting the consensus estimate of ($0.21).

A number of other analysts have also recently weighed in on the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of DiaMedica Therapeutics in a research report on Thursday, October 15th. Wall Street Zen lowered DiaMedica Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, DiaMedica Therapeutics presently has a consensus rating of "Hold" and an average price target of $12.00.

View Our Latest Stock Analysis on DMAC

DiaMedica Therapeutics Stock Up 0.6%

Shares of DMAC stock opened at $8.38 on Wednesday. The business has a 50 day moving average of $8.27 and a two-hundred day moving average of $7.20. DiaMedica Therapeutics has a 52 week low of $5.24 and a 52 week high of $11.00. The company has a market cap of $452.18 million, a P/E ratio of -11.03 and a beta of 0.95.

Hedge Funds Weigh In On DiaMedica Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. raised its stake in DiaMedica Therapeutics by 11.5% during the 3rd quarter. Goldman Sachs Group Inc. now owns 187,465 shares of the company's stock valued at $1,550,000 after acquiring an additional 19,399 shares in the last quarter. Squarepoint Ops LLC acquired a new position in DiaMedica Therapeutics during the 2nd quarter worth $1,023,000. Bank of New York Mellon Corp acquired a new position in DiaMedica Therapeutics during the 2nd quarter worth $829,000. Sei Investments Co. grew its stake in shares of DiaMedica Therapeutics by 100.0% in the first quarter. Sei Investments Co. now owns 111,320 shares of the company's stock worth $754,000 after purchasing an additional 55,660 shares in the last quarter. Finally, AWM Investment Company Inc. grew its stake in shares of DiaMedica Therapeutics by 80.8% in the third quarter. AWM Investment Company Inc. now owns 65,097 shares of the company's stock worth $538,000 after purchasing an additional 29,097 shares in the last quarter. 10.12% of the stock is currently owned by institutional investors and hedge funds.

About DiaMedica Therapeutics

(Get Free Report)

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company developing treatments for serious diseases, with a focus on preeclampsia and neurological conditions. Its lead candidate, DM199 (rinvecalinase alfa), is a recombinant form of human tissue kallikrein-1, an enzyme involved in regulating blood flow. DiaMedica is investigating DM199 for acute ischemic stroke and preeclampsia; it remains an investigational drug and is not approved for commercial use. The company is headquartered in Minneapolis, Minnesota, and conducts clinical development of its therapies.

See Also

Earnings History and Estimates for DiaMedica Therapeutics (NASDAQ:DMAC)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in DiaMedica Therapeutics Right Now?

Before you consider DiaMedica Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DiaMedica Therapeutics wasn't on the list.

While DiaMedica Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines